Myocardial ischemia pathway

The myocardial ischemia pathway encompasses a complex network of signaling and metabolic pathways that are activated in heart tissue when oxygen supply is inadequate due to reduced blood flow (ischemia), as occurs in myocardial infarction (MI). Key molecular cascades include those mediating inflammation (e.g., NLRP3/caspase-1, TLR4/NF-κB), apoptosis, autophagy, oxidative stress (e.g., Nrf2/HO-1), fibrosis (e.g., TGF-β/SMAD, Wnt/β-catenin), angiogenesis (e.g., PI3K/Akt, JAK/STAT, MAPK), calcium homeostasis, and metabolic regulation (e.g., AMPK, sirtuins, glycolysis, mitochondrial metabolism). While these individual molecules and signaling nodes are therapeutic targets, the "myocardial ischemia pathway" is a conceptual summary of these interrelated processes and not itself a druggable molecular entity. In summary, "myocardial ischemia pathway" is not the proper name for a target but a catch-all description for the signaling events and molecular interactions during cardiac ischemia and reperfusion injury. The correct approach is to specify particular molecules or signaling nodes (such as "PI3K/Akt pathway," "Beta-1 adrenergic receptor," "NLRP3 inflammasome," etc.) for actionable drug discovery or biological annotation.

Other names

Myocardial ischemia signaling pathwayCardiac ischemia pathwayIschemia-reperfusion injury pathways

Anti-inflammatory modulation; Reduction of calcium overload; Inhibition of apoptosis; Antioxidant effects; Vasodilation; Modulation of signaling pathways (e.g., PI3K/Akt, MAPK, JAK/STAT, Wnt/β-catenin, calcium signaling, TGF-β/SMAD, RhoA/ROCK, Notch, Hippo/YAP, NLRP3/caspase-1)